Human leukocyte antigen and tumor immunotherapy (Review)
- Da-Hua Liu
- Fei-Fei Mou
- Min An
- Pu Xia
Affiliations: Biological Anthropology Institute, College of Basic Medical Science, Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Nursing, Shijiazhuang Medical College, Shijiazhuang, Hebei 050599, P.R. China, Department of Cardiology, Jinzhou Central Hospital, Jinzhou, Liaoning, 121001, P.R. China
- Published online on: April 26, 2023 https://doi.org/10.3892/ijo.2023.5516
- Article Number: 68
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Malignant tumors seriously endanger human health and life, and restrict economic development. Human leukocyte antigen (HLA) is the expression product of the human major histocompatibility complex, which, at present, is the most complex known polymorphic system. The polymorphism and expression of HLA molecules have been demonstrated to be associated with the occurrence and development of tumors. HLA molecules can regulate the proliferation of tumor cells and inhibit antitumor immunity. In the present review, the structure and function of HLA molecules, the polymorphism and expression of HLA in tumor tissue, the roles of HLA in tumor cells and tumor immunity, and the potential clinical application of HLA in tumor immunotherapy are summarized. The overall aim of the present review is to provide relevant information for the development of antitumor immunotherapies involving HLA in the clinic.